TransMedics Group Inc (NAS:TMDX)
$ 59.64 -1.38 (-2.26%) Market Cap: 2.00 Bil Enterprise Value: 2.24 Bil PE Ratio: 63.45 PB Ratio: 9.53 GF Score: 70/100

Transmedics Group Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 12:00PM GMT
Release Date Price: $32.1 (+1.71%)
Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst

(technical difficulty)

have to get here.

Questions & Answers

Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst

And on the heels of the panel meeting last spring, we're expecting approval with somewhat of a restricted label, the label you ultimately received is very broad. Can you just talk about the label relative to what you were expecting and walk through areas of upside for OCS utilization based on the broad label versus your expectations?

Waleed H. Hassanein
TransMedics Group, Inc. - Founder, MD, CEO, President & Director

Sure. Thank you, Cecilia. The label final language was not a surprise for us. We've always stated post panel that we were fairly confident that after the final label has to reflect the patient population that were studied at the -- in the EXPAND trial. So the final label wasn't too much of a surprise for us. We just had to wait for it to be formalized and announced.

The

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot